Back to resultsBuprenorphine Pharmacology Related to Addiction Treatment - 21
Primary Purpose
Opioid-Related Disorders
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Buprenorphine
Sponsored by
About this trial
This is an interventional treatment trial for Opioid-Related Disorders
Eligibility Criteria
Please contact site for information.
Sites / Locations
- Treatment Research Center
Outcomes
Primary Outcome Measures
Drug use
Opioid agonist effects
Opiate withdrawal
Physiological changes in: pupil diameter, blood pressure, heart rate, respiration
Secondary Outcome Measures
Full Information
NCT ID
NCT00000239
First Posted
September 20, 1999
Last Updated
August 16, 2005
Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
University of Vermont
1. Study Identification
Unique Protocol Identification Number
NCT00000239
Brief Title
Buprenorphine Pharmacology Related to Addiction Treatment - 21
Official Title
Buprenorphine Pharmacology Related to Addiction Treatment
Study Type
Interventional
2. Study Status
Record Verification Date
December 2002
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
University of Vermont
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to examine if chronic buprenorphine administration will generate supersensitivity to opiates.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid-Related Disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Enrollment
0 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Buprenorphine
Primary Outcome Measure Information:
Title
Drug use
Title
Opioid agonist effects
Title
Opiate withdrawal
Title
Physiological changes in: pupil diameter, blood pressure, heart rate, respiration
10. Eligibility
Sex
All
Minimum Age & Unit of Time
0 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Please contact site for information.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Warren Bickel, Ph.D.
Organizational Affiliation
University of Vermont
Official's Role
Principal Investigator
Facility Information:
Facility Name
Treatment Research Center
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
12. IPD Sharing Statement
Citations:
Citation
Bickel, Amass (1995 Experimental & Clinical Psychopharmacology. 3: 477-489 Amass et al 91996) Journal of Substance Abuse Treatment. 13: 43-49 Madden et al., (1997) Experimental & Clinical Psychopharmacology. 5: 1-7. Bickel, Amass (1995) Experimental & Clinical Psychopharmacology. 3: 477-489. Amass et al., (1996) Journal of Substance Abuse Treatment. 13:43-49. Madden et al., (1997) ) Experimental & Clinical Psychopharmacology. 5:1-7.
Results Reference
background
Learn more about this trial
Buprenorphine Pharmacology Related to Addiction Treatment - 21
We'll reach out to this number within 24 hrs